背景 廣元市410醫(yī)院于2003年2月、4月分兩批共收治6例SARS確診病人,至今已治愈5例,4月25日成為四川SARS定點(diǎn)醫(yī)院.
目的 評(píng)價(jià)SARS定點(diǎn)醫(yī)院防治費(fèi)用及對(duì)醫(yī)院收入和運(yùn)作的影響.方法:從定點(diǎn)醫(yī)院的觀點(diǎn),以治愈率為臨床效果指標(biāo),回顧性評(píng)價(jià)SARS確診和疑似病人的治療費(fèi)用,定點(diǎn)醫(yī)院總體防治的費(fèi)用,SARS定點(diǎn)醫(yī)院對(duì)總體、醫(yī)療和藥品收入,門診和住院就診病人的影響.敏感性分析評(píng)價(jià)院內(nèi)感染和治愈率的變化對(duì)費(fèi)用的影響.
結(jié)果 5例確診,6例疑似病人均治愈.人均治療費(fèi)用分別為7866和4273元,醫(yī)療費(fèi)用分別為14983.86和5494.92元.除藥物支持治療外,其余各項(xiàng)費(fèi)用在確診和疑似病人間無(wú)統(tǒng)計(jì)學(xué)意義.SARS定點(diǎn)醫(yī)院總體防治費(fèi)用為174.45萬(wàn)元.指定為定點(diǎn)醫(yī)院前后,醫(yī)院收入和門診、住院人數(shù)分別下降33.45%,43.62%和47.33%.
結(jié)論 SARS確診病人費(fèi)用為14983.86元.定點(diǎn)醫(yī)院將明顯影響醫(yī)院收入和運(yùn)作.
引用本文： 孫鑫,李幼平,黃鷗寧,何運(yùn)昉,沈驥,鄺璞. 嚴(yán)重急性呼吸綜合征(SARS)定點(diǎn)醫(yī)院防治費(fèi)用評(píng)價(jià)及對(duì)醫(yī)院經(jīng)濟(jì)的影響. 中國(guó)循證醫(yī)學(xué)雜志, 2003, 03(2): 135-141. doi: 復(fù)制
| 1. | ［1］Jefferson T, Dernicheli V, Deeks J, Rivetti D Neuraminidase in hibitors for preventing and treating influenza in healthy adults CSR [M/CD] CL 2003 - 1. |
| 2. | ［2］Donald R. Husereau, B. Sc. Pharm M. Sc. 1 Bruce Brady , M. A ,M. Sc. 1 Allison McGeer MD, FRCPC2Oseltamivir for the treeatment of suspected influenza a clinical and economic assessmeont[R]. CCOHTA Issue 21 2001. |
| 3. | ［3］Burls A, Clark W, Stewart T, Preston C, Bryan S, Jefferson T,et al. Zanamivir [or the treatment of influenza in adults: a system atic review and economie evaluation. HTA 2002; 6 (9). NHS R&D HTA Programme. |
| 4. | ［4］Full Guidance on the the use of zanamivir, oseltamivir and amantadine for the treatment of influenza Tecbnology Appraisal Guidance No. 58 [S] NHS February 2003. |
| 5. | ［5］Do neuraminidase inhibitors prevent influenza [R] CCOHTA. Issue 27 November 2001. |
| 6. | ［6］Treating influenza by medication - Zanamivir SBU Alert May 22,2001. |
| 7. | ［7］Gideon Koren, Susan King, Sandra Knowles, Elizabeth PhillipsRibavirin in the treatment of SARS: A new trick for auold drug [J]? JAMC 13 MAI 2003; 168 (10). |
| 8. | ［8］Jefferson TO, Tyrrell D Antivirals for the Common Cold CSR [M/CD]CL 2003- 1. |
| 9. | ［9］Randolph AG, Wang EEL Ribavirin for respiratory syncytial virns infection of the lower respiratory tract CSR [ M/CD ] CL 2003-1. |
- 1. ［1］Jefferson T, Dernicheli V, Deeks J, Rivetti D Neuraminidase in hibitors for preventing and treating influenza in healthy adults CSR [M/CD] CL 2003 - 1.
- 2. ［2］Donald R. Husereau, B. Sc. Pharm M. Sc. 1 Bruce Brady , M. A ,M. Sc. 1 Allison McGeer MD, FRCPC2Oseltamivir for the treeatment of suspected influenza a clinical and economic assessmeont[R]. CCOHTA Issue 21 2001.
- 3. ［3］Burls A, Clark W, Stewart T, Preston C, Bryan S, Jefferson T,et al. Zanamivir [or the treatment of influenza in adults: a system atic review and economie evaluation. HTA 2002; 6 (9). NHS R&D HTA Programme.
- 4. ［4］Full Guidance on the the use of zanamivir, oseltamivir and amantadine for the treatment of influenza Tecbnology Appraisal Guidance No. 58 [S] NHS February 2003.
- 5. ［5］Do neuraminidase inhibitors prevent influenza [R] CCOHTA. Issue 27 November 2001.
- 6. ［6］Treating influenza by medication - Zanamivir SBU Alert May 22,2001.
- 7. ［7］Gideon Koren, Susan King, Sandra Knowles, Elizabeth PhillipsRibavirin in the treatment of SARS: A new trick for auold drug [J]? JAMC 13 MAI 2003; 168 (10).
- 8. ［8］Jefferson TO, Tyrrell D Antivirals for the Common Cold CSR [M/CD]CL 2003- 1.
- 9. ［9］Randolph AG, Wang EEL Ribavirin for respiratory syncytial virns infection of the lower respiratory tract CSR [ M/CD ] CL 2003-1.